EMBLEM Technology Transfer

Dr. Gábor M. Lamm serves as Managing Director, with Dr. Jürgen Bauer as Deputy Managing Director. The team operates as a lean, centralized unit where invention assessment, IP strategy, and spin-off formation decisions are driven by EMBLEM's in-house business development and intellectual property staff, all of whom hold scientific backgrounds relevant to EMBL's research domains.

EMBLEM's deal flow is captive and exclusive — it originates entirely from the European Molecular Biology Laboratory's six research sites across Germany, the UK, France, Italy, and Spain. EMBLEM identifies and protects inventions directly from EMBL scientists, alumni, and in some cases third parties linked to EMBL, managing a pipeline of over 1,000 inventions and 450 patents. This creates a proprietary funnel unmatched by any external investor.

EMBLEM operates primarily as a technology transfer office with private equity characteristics, not a conventional VC firm. It is the wholly owned commercial subsidiary of EMBL, performing classical technology transfer tasks — patenting, licensing, and spin-off formation — without raising external funds for its own balance sheet. EMBL Ventures, a related entity, manages the EMBL Technology Fund, which provides venture capital to the spin-offs EMBLEM creates.

EMBLEM focuses on direct commercialization through licensing agreements and the creation of spin-off companies from EMBL research. It does not operate as a fund-of-funds or commit capital to external managers. The EMBL Technology Fund, managed by EMBL Ventures, invests directly into the spin-offs, and EMBLEM itself negotiates collaborative research agreements and consultancy service contracts.

EMBLEM targets the very earliest stages of company formation — spin-offs and seed-stage ventures built directly from EMBL laboratory discoveries. Startups are supported from business-plan drafting through physical incubation space and initial public or venture funding identification. Most portfolio companies are pre-clinical or early-commercial life-science and instrumentation firms.

EMBLEM's portfolio is exclusively life sciences, driven by EMBL's research mission. Core sectors include structural biology, genomics, proteomics, epigenetic editing, AI-driven computational biophysics, and advanced scientific instrumentation. Representative spin-offs include Epitome Therapeutics (epigenetic editing), DenovAI Biotech (AI computational biophysics), and Luxendo (advanced microscopy).

EMBLEM is the wholly owned commercial subsidiary and exclusive technology and knowledge transfer partner of EMBL, an intergovernmental organization with 29 member states. EMBLEM operates from EMBL's Heidelberg headquarters and serves all six EMBL sites. The relationship gives EMBLEM privileged access to all commercially relevant intellectual property generated by EMBL researchers, a structural arrangement that eliminates competition for deal sourcing.